At @ months , the rate of the first coprimary efficacy endpoint ( composite of stroke , systemic embolism -LSB- SE -RSB- , and cardiovascular/unexplained death ) was @ in the device group versus @ in the control group ( rate ratio @ -LSB- @ % credible interval ( CrI ) : @ to @ -RSB- ) and did not achieve the prespecified criteria noninferiority ( upper boundary of @ % CrI @ ) .